Xavion Lifesciences, LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Feb 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 5, 2027The maintenance fee for Liquid pharmaceutical formulations of apixaban (US 11,833,138) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
- 1 fee due Jul 23, 2027The maintenance fee for Pharmaceutical formulations of tafamidis (US 11,878,081) comes due Jul 23, 2027. Unpaid by Jan 24, 2028, it lapses early.
- 1 fee due Nov 14, 2027The maintenance fee for Liquid pharmaceutical formulations of tafamidis (US 11,980,685) comes due Nov 14, 2027. Unpaid by May 15, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 23, 2026
- Sep 13 US 11,439,760 Syringes · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,345,772 | Liquid levothyroxine formulations In force · USPTO record | In force | USPTO record | |
| US 9,393,243 | Topical Ciprofloxacin compositions In force · USPTO record | In force | USPTO record | |
| US 11,878,081 | Pharmaceutical formulations of tafamidis In force · USPTO record | In force | USPTO record | |
| US 11,980,685 | Liquid pharmaceutical formulations of tafamidis In force · USPTO record | In force | USPTO record | |
| US 12,042,491 | Pharmaceutical formulations of quinolines In force · USPTO record | In force | USPTO record | |
| US 11,833,138 | Liquid pharmaceutical formulations of apixaban In force · USPTO record | In force | USPTO record | |
| US 12,109,188 | Liquid Pharmaceutical Formulations of Topiramate In force · High confidence | In force | High confidence | |
| US 12,290,504 | Aqueous Formulations of Topiramate In force · High confidence | In force | High confidence |
Also on record, not counted in the 8: 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.